BRPI0823234A2 - nanovesícula para liberação de um agente para uma membrana biológica e processo para direcionar um agente para uma membrana de uma célula ou um tecido. - Google Patents

nanovesícula para liberação de um agente para uma membrana biológica e processo para direcionar um agente para uma membrana de uma célula ou um tecido.

Info

Publication number
BRPI0823234A2
BRPI0823234A2 BRPI0823234A BRPI0823234A BRPI0823234A2 BR PI0823234 A2 BRPI0823234 A2 BR PI0823234A2 BR PI0823234 A BRPI0823234 A BR PI0823234A BR PI0823234 A BRPI0823234 A BR PI0823234A BR PI0823234 A2 BRPI0823234 A2 BR PI0823234A2
Authority
BR
Brazil
Prior art keywords
agent
nanovesicle
directing
releasing
tissue
Prior art date
Application number
BRPI0823234A
Other languages
English (en)
Inventor
Qi Xiaoyang
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of BRPI0823234A2 publication Critical patent/BRPI0823234A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0823234A 2008-11-07 2008-11-07 nanovesícula para liberação de um agente para uma membrana biológica e processo para direcionar um agente para uma membrana de uma célula ou um tecido. BRPI0823234A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/082805 WO2010053489A1 (en) 2008-11-07 2008-11-07 Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems

Publications (1)

Publication Number Publication Date
BRPI0823234A2 true BRPI0823234A2 (pt) 2019-09-24

Family

ID=42153126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0823234A BRPI0823234A2 (pt) 2008-11-07 2008-11-07 nanovesícula para liberação de um agente para uma membrana biológica e processo para direcionar um agente para uma membrana de uma célula ou um tecido.

Country Status (8)

Country Link
US (1) US20120020878A1 (pt)
EP (1) EP2365796A4 (pt)
JP (1) JP2012508233A (pt)
CN (1) CN102264349A (pt)
AU (1) AU2008363813A1 (pt)
BR (1) BRPI0823234A2 (pt)
CA (1) CA2742831A1 (pt)
WO (1) WO2010053489A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541307A (zh) * 2006-10-20 2009-09-23 儿童医院医疗中心 自发形成的椭圆体磷脂单层囊泡
DK3135301T3 (en) 2010-06-22 2018-06-25 Onxeo OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC SUBSTANCES FOR NUCLEIC ACID CONJUGATES
CN108926535B (zh) * 2011-02-01 2020-12-29 常州长吉生物技术开发有限公司 SapC-磷脂纳米囊泡冻干制剂、 其制备方法及用途
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
ES2608857T3 (es) 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
SI3043814T1 (sl) 2013-09-13 2021-04-30 Salipro Biotech AB, Greenhouse Labs Antigen in postopek za proizvodnjo le-tega
CN106573220B (zh) * 2014-07-24 2019-08-16 凸版印刷株式会社 脂质膜结构体、脂质膜结构体固定化载体、及胞体的融合方法
US10570173B2 (en) * 2015-01-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Protease-activated contrast agents for in vivo imaging
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US10493172B2 (en) 2016-06-02 2019-12-03 California Institute Of Technology Gas-filled structures and related compositions, methods and systems to image a target site
US11118210B2 (en) 2016-07-28 2021-09-14 California Institute Of Technology Genetically engineered gas vesicle gene clusters, genetic circuits, vectors, prokaryotic cells, compositions, methods and systems for contrast-enhanced imaging
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
EP3768246B1 (en) * 2018-03-23 2021-08-25 Bexion Pharmaceuticals, Inc. Saposin c pharmaceutical compositions and their use in treating cancer
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
CA3120082A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US11761008B2 (en) 2019-01-07 2023-09-19 California Institute Of Technology Gas vesicle expression systems, gas vesicle constructs and related genetic circuits, vectors, mammalian cells, hosts, compositions, methods and systems
WO2020146367A1 (en) 2019-01-07 2020-07-16 California Institute Of Technology Burst ultrasound reconstruction with signal templates and related methods and systems
PL3850089T3 (pl) 2019-02-04 2024-05-06 Freeline Therapeutics Limited Polinukleotydy
IL285020B2 (en) * 2019-02-06 2025-11-01 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
WO2020198728A1 (en) * 2019-03-28 2020-10-01 California Institute Of Technology Compositions, methods and systems for gas vesicle based cavitation
WO2021183596A1 (en) * 2020-03-10 2021-09-16 University Of Cincinnati Materials and methods for the treatment of gaucher disease
WO2022031554A1 (en) * 2020-08-03 2022-02-10 Silo Pharma, Inc. Central nervous system delivery of nonsteroidal anti-inflammatory drugs
AU2022253020A1 (en) 2021-04-08 2023-10-26 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872406B2 (en) * 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
EP2020988B1 (en) * 2006-04-28 2017-08-16 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
CN101541307A (zh) * 2006-10-20 2009-09-23 儿童医院医疗中心 自发形成的椭圆体磷脂单层囊泡
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents

Also Published As

Publication number Publication date
WO2010053489A1 (en) 2010-05-14
CA2742831A1 (en) 2010-05-14
CN102264349A (zh) 2011-11-30
JP2012508233A (ja) 2012-04-05
EP2365796A1 (en) 2011-09-21
AU2008363813A1 (en) 2010-05-14
EP2365796A4 (en) 2015-04-29
US20120020878A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
BRPI0822756A2 (pt) sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0924350A2 (pt) Dispositivo de ultrassom compreendendo meio para gerar feixe de ultrassom que apresenta um formato de segmento côncavo tendo uma curvatura única
BRPI0906612A2 (pt) Composição para preservar células, tecidos e órgãos, e, métodos para usar a composição e de preparação de uima composição
BRPI0821393A2 (pt) Fermentação não estéril de bioetanol
PT2257155T (pt) Criopreservação de células e tecidos biológicos
BRPI1007545A2 (pt) composição aquosa, e, processo para aperfeiçoar tratamento de cabelo
BRPI0917250A2 (pt) sistema para detecção de tecido em um paciente, sistema para detectar característica de tecido em um paciente
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
BRPI0919083A2 (pt) processo para preparação de uma membrana, e, membrana assimétrica.
BRPI0817198A2 (pt) (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI0822633A2 (pt) Desinfetante, e, método de esterilização.
BRPI0815054A2 (pt) Método e aparelho de speração de membrana.
EP2503337A4 (en) ORGANIC DYED MICROPARTICLES, DIAGNOSIS AGENTS WITH IT AND IN VITRO DIAGNOSTIC PROCEDURES
BRPI0923158A2 (pt) membrana de polímero microporoso modificada por polímero aquoso, método de produção e uso da mesma.
DK2375907T3 (da) Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
BRPI1009981A2 (pt) sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
BRPI0717758A2 (pt) Processo para geração de proteína e usos das mesmas
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BRPI0906892A2 (pt) "método para a obtenção de um produto em um bioreator, sistema para a obtenção de um produto que compreende um bioreator, bioreator, bioreator para a fermentação de um produto biológico no suporte sólido e método para a obtenção de um produto biológico"
BRPI0919020A8 (pt) terapia celular de tecido isquêmico
BRPI0920419A2 (pt) pinça para o osso e a pele.
BRPI0812771A2 (pt) Método para a detecção e diagnóstico in vitro de uma infecção por um microorganismo, conjunto de reagentes para a realização do método de detecção .
BRPI0922574A2 (pt) processo para purificar metil metacrilato, metil metacrilato, e, polímero.
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.